Trial Profile
ER metastatic HER2 + breast cancer in men and CKD fulvestant 4/6 inhibitor palbociclib kezelesae multiple prior chemotherapy, endocrine therapy and molecular targeted therapy after [Metasztatikus ER+ HER2- ferfi emlorak fulvestant es CKD 4/6 inhibitor palbociclib kezelesae tobbszoros megelozo kemoterapia, endokrin terapia es molekularis celzott terapia utan]
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2014
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Nov 2014 New trial record